What is HC Wainwright’s Forecast for LXRX FY2024 Earnings?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Stock analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Lexicon Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings of ($0.76) per share for the year, down from their prior estimate of ($0.73). HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ Q4 2024 earnings at ($0.15) EPS, FY2025 earnings at ($0.60) EPS and FY2026 earnings at ($0.47) EPS.

A number of other research analysts also recently weighed in on the company. Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Wednesday. Leerink Partners set a $6.00 price target on shares of Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research report on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $6.00.

Lexicon Pharmaceuticals Stock Down 2.8 %

LXRX stock opened at $1.06 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 11.49 and a current ratio of 11.51. Lexicon Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $3.73. The stock’s fifty day moving average price is $1.64 and its 200-day moving average price is $1.74.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

A number of institutional investors have recently bought and sold shares of LXRX. CVI Holdings LLC bought a new stake in Lexicon Pharmaceuticals during the second quarter valued at about $34,000. Principal Financial Group Inc. grew its stake in shares of Lexicon Pharmaceuticals by 116.1% during the 2nd quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 12,225 shares during the period. Great Point Partners LLC purchased a new stake in Lexicon Pharmaceuticals in the 2nd quarter worth approximately $50,000. BNP Paribas Financial Markets raised its stake in Lexicon Pharmaceuticals by 71.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 13,246 shares during the period. Finally, Virtu Financial LLC purchased a new position in Lexicon Pharmaceuticals during the first quarter valued at approximately $105,000. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.